Duke University Medical Center in Durham, North Carolina and Rush University Medical Center in Chicago, Illinois are now recruiting individuals to participate in a two-year prospective observational study of males with Creatine Transporter Deficiency (CTD), named the Vigilan Study. Dwight Koerberl, MD, PhD is the principal investigator (PI) at Duke University, and Elizabeth Berry-Kravis, MD, […]

READ MORE

Austin, Texas – March 15, 2017 ScreenCreatine Project: Disease awareness website launched to expand understanding and resources associated with Cerebral Creatine Deficiency Syndromes (CCDS) including Creatine Transporter Deficiency (CTD) Today, Lumos Pharma launches the disease awareness website ScreenCreatine.org, part of the ScreenCreatine Project.  ScreenCreatine.org was developed to provide health literate information about the three creatine […]

READ MORE

One in ten individuals are living with a rare disease.   On the last day of February every year, hundreds of patient organizations from more than 80 countries conduct awareness-raising activities to celebrate Rare Disease Day. In honor of the 10th annual Rare Disease Day, Lumos Pharma has created the below video “Screen Creatine NOW!” in […]

READ MORE

The Lumos Team supports CCDS Awareness Day. Thank you Association for Creatine Deficiencies – ACD – for organizing this day!  

READ MORE

Austin, Texas – June 21, 2016 – Lumos Pharma, Inc. has further expanded its management team with the appointment of Carol A. Dutch as Senior Director, Patient Engagement. Ms. Dutch will create and lead global patient engagement projects to support the clinical development and pre-commercial phases of Lumos’ rare and orphan disease pipeline projects. Over […]

READ MORE